Behavior Enhances Drug Reduction of Incontinence (BE-DRI)

Behavior Enhances Drug Reduction of Incontinence

The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.

Inclusion:

• Female
• Urge predominant incontinence
• Incontinent > 3 mos
• Available for 8 mos of followup

Exclusion:

• Pregnancy or < 6 mos post-partum
• Hypersensitivity to drug (tolterodine)
• Systemic disease that affects bladder function (e.g., Parkinson's disease, Multiple Sclerosis, spinal cord injury)
• History of extensive behavior treatment